HLS Therapeutics Management
Management criteria checks 1/4
HLS Therapeutics' CEO is Craig Millian, appointed in May 2023, has a tenure of 1.42 years. total yearly compensation is $1.41M, comprised of 26.9% salary and 73.1% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth €31.13K. The average tenure of the management team and the board of directors is 3.9 years and 1.9 years respectively.
Key information
Craig Millian
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 26.9% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.04% |
| Management average tenure | 3.9yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$1m | US$381k | -US$28m |
Compensation vs Market: Craig's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD501.82K).
Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.
CEO
Craig Millian (56 yo)
1.4yrs
Tenure
US$1,414,327
Compensation
Mr. Craig Stuart Millian, MBA, is Chief Executive Officer and Director of HLS Therapeutics Inc. from May 1, 2023. He served as Chief Operating Officer at Corbus Pharmaceuticals Holdings, Inc. since Septemb...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$1.41m | 0.039% $ 31.1k | |
| Interim CFO & Non-Independent Director | less than a year | US$110.39k | 0.025% $ 19.9k | |
| Vice President of Scientific Affairs | 10.3yrs | US$313.47k | 0.16% $ 123.8k | |
| Senior VP of Legal | 6.4yrs | US$418.09k | 0.0016% $ 1.2k | |
| Senior Vice President of Commercial | 1.3yrs | US$437.71k | 0.0038% $ 3.0k | |
| VP & Corporate Controller | 6.8yrs | no data | no data |
3.9yrs
Average Tenure
56yo
Average Age
Experienced Management: 74D's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$1.41m | 0.039% $ 31.1k | |
| Interim CFO & Non-Independent Director | 1.3yrs | US$110.39k | 0.025% $ 19.9k | |
| Independent Chairman of the Board | 3.3yrs | US$248.89k | 0.31% $ 241.6k | |
| Independent Director | 6.6yrs | US$220.00k | no data | |
| Independent Director | 3.3yrs | US$207.50k | 0.0016% $ 1.2k | |
| Independent Director | 1.9yrs | US$209.50k | 0.0056% $ 4.4k | |
| Independent Director | 1.3yrs | US$112.49k | no data |
1.9yrs
Average Tenure
56yo
Average Age
Experienced Board: 74D's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.